Zobrazeno 1 - 10
of 98
pro vyhledávání: '"Lianchun Xiao"'
Autor:
Curtis A Lachowiez, Patrick K Reville, Hagop Kantarjian, Elias Jabbour, Gautam Borthakur, Naval Daver, Sanam Loghavi, Ken Furudate, Lianchun Xiao, Sherry Pierce, Nicholas J Short, Abhishek Maiti, Musa Yilmaz, Koji Sasaki, Koichi Takahashi, Marina Konopleva, Naveen Pemmaraju, Uday Popat, Elizabeth Shpall, Guillermo Garcia-Manero, Farhad Ravandi, Courtney D DiNardo, Tapan M Kadia
Publikováno v:
The Lancet Haematology. 9:e350-e360
Venetoclax combined with intensive chemotherapy has been shown to be safe with promising activity in fit patients with newly diagnosed acute myeloid leukaemia. The aim of this study was to compare the activity of venetoclax plus intensive chemotherap
Autor:
Ahmed Omar Kaseb, Elshad Hasanov, Hop Sanderson Tran Cao, Lianchun Xiao, Jean-Nicolas Vauthey, Sunyoung S Lee, Betul Gok Yavuz, Yehia I Mohamed, Aliya Qayyum, Sonali Jindal, Fei Duan, Sreyashi Basu, Shalini S Yadav, Courtney Nicholas, Jing Jing Sun, Kanwal Pratap Singh Raghav, Asif Rashid, Kristen Carter, Yun Shin Chun, Ching-Wei David Tzeng, Divya Sakamuri, Li Xu, Ryan Sun, Vittorio Cristini, Laura Beretta, James C Yao, Robert A Wolff, James Patrick Allison, Padmanee Sharma
Publikováno v:
Lancet Gastroenterol Hepatol
Kaseb, A O, Hasanov, E, Cao, H S T, Xiao, L, Vauthey, J N, Lee, S S, Yavuz, B G, Mohamed, Y I, Qayyum, A, Jindal, S, Duan, F, Basu, S, Yadav, S S, Nicholas, C, Sun, J J, Singh Raghav, K P, Rashid, A, Carter, K, Chun, Y S, Tzeng, C W D, Sakamuri, D, Xu, L, Sun, R, Cristini, V, Beretta, L, Yao, J C, Wolff, R A, Allison, J P & Sharma, P 2022, ' Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma : a randomised, open-label, phase 2 trial ', The Lancet Gastroenterology and Hepatology, vol. 7, no. 3, pp. 208-218 . https://doi.org/10.1016/S2468-1253(21)00427-1
Kaseb, A O, Hasanov, E, Cao, H S T, Xiao, L, Vauthey, J N, Lee, S S, Yavuz, B G, Mohamed, Y I, Qayyum, A, Jindal, S, Duan, F, Basu, S, Yadav, S S, Nicholas, C, Sun, J J, Singh Raghav, K P, Rashid, A, Carter, K, Chun, Y S, Tzeng, C W D, Sakamuri, D, Xu, L, Sun, R, Cristini, V, Beretta, L, Yao, J C, Wolff, R A, Allison, J P & Sharma, P 2022, ' Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma : a randomised, open-label, phase 2 trial ', The Lancet Gastroenterology and Hepatology, vol. 7, no. 3, pp. 208-218 . https://doi.org/10.1016/S2468-1253(21)00427-1
Background: Hepatocellular carcinoma has high recurrence rates after surgery; however, there are no approved standard-of-care neoadjuvant or adjuvant therapies. Immunotherapy has been shown to improve survival in advanced hepatocellular carcinoma; we
Autor:
Koichi Takahashi, Nitin Jain, Guillermo Garcia-Manero, Lucia Masarova, Sa Wang, Courtney D. DiNardo, Naveen Pemmaraju, Guillermo Montalban Bravo, Tapan M. Kadia, Sanam Loghavi, Musa Yilmaz, Ghayas C. Issa, Koji Sasaki, Elias Jabbour, Steven M. Kornblau, Abhishek Maiti, Marina Konopleva, Lianchun Xiao, Curtis Lachowiez, Maria Adeoti, Farhad Ravandi, Michael Andreeff, Nicholas J. Short, Gautam Borthakur, Hagop M. Kantarjian, Naval Daver, Yesid Alvarado
Publikováno v:
J Clin Oncol
PURPOSE Sixty percent of newly diagnosed patients with acute myeloid leukemia (ND-AML) receiving frontline therapy attain a complete response (CR), yet 30%-40% of patients relapse. Relapsed or refractory AML (R/R-AML) remains a particularly adverse p
Autor:
Ying Wang, Arlene M. Correa, Boyi Gan, Randy L. Johnson, Ailing W. Scott, Cordelia Y Li, Melissa Pool Pizzi, Jeannelyn S. Estrella, Longfei Huo, Shaozhong Wei, Lianchun Xiao, Brian Weston, Namita Shanbhag, Shumei Song, Yuan Li, Wayne L. Hofstetter, Guang Lei, Lang Ma, Jaffer A. Ajani, Manoop S. Bhutani, Bin Liu, Jeffrey H. Lee, Qiongrong Chen, Jiankang Jin
Publikováno v:
Gut
ObjectiveGastro-oesophageal cancers (GEC) are resistant to therapy and lead to poor prognosis. The cancer stem cells (CSCs) and antiapoptotic pathways often confer therapy resistance. We sought to elucidate the antitumour action of a BCL-2 inhibitor,
Autor:
Kanwal Pratap Singh Raghav, Milind Javle, Robert A. Wolff, Lianchun Xiao, Michael J. Overman, Chirayu Mohindroo, Florencia McAllister, Rachna T. Shroff, Jane E. Rogers, David R. Fogelman, Gauri R. Varadhachary, Shubham Pant, Jonathan D. Mizrahi
Publikováno v:
Cancer Medicine, Vol 9, Iss 15, Pp 5406-5415 (2020)
Cancer Medicine
Cancer Medicine
Background Gemcitabine (GEM) plus nab‐paclitaxel (NabP) (GEM 1000 mg/m2 IV over 30 minutes + NabP 125 mg/m2 IV given days 1, 8, and 15 every 28 days) is one of the two standard of care combination therapies for metastatic pancreatic ductal adenocar
Autor:
Debra Nana Yeboa, Laurence D. Rhines, David Boyce-Fappiano, Behrang Amini, Claudio E. Tatsui, Olsi Gjyshi, Andrew J. Bishop, Ahmed Kaseb, Ethan B. Ludmir, Todd A. Pezzi, Amol J. Ghia, Lianchun Xiao, Tina Marie Briere, Jing Li
Publikováno v:
Journal of Neuro-Oncology. 148:327-334
Dose escalation via stereotactic radiation therapy techniques has been necessary for hepatobiliary malignancies in the primary and oligometastatic setting, but such dose escalation is challenging for spine metastases due to spinal cord proximity. Her
Autor:
Nora M. Navone, Paul G. Corn, Sumit K. Subudhi, Mark Titus, Cristian Coarfa, Graciela M. Nogueras-Gonzalez, Amado J. Zurita, Christopher J. Logothetis, Patricia Troncoso, Shixia Huang, Shi Ming Tu, Theocharis Panaretakis, Sumankalai Ramachandran, Kimal Rajapakshe, Sue Hwa Lin, Gary E. Gallick, Eleni Efstathiou, Lianchun Xiao, Guocan Wang, Ana Aparicio, Miao Zhang
Publikováno v:
Clinical Cancer Research. 26:990-999
Purpose: Cabozantinib, an oral inhibitor of c-MET/VEGFR2 signaling, improved progression-free survival (mPFS) but not overall survival (OS) in metastatic castrate-resistant prostate cancer. We evaluated cabozantinib plus androgen deprivation therapy
Autor:
Michael J. Overman, Ryan W. Huey, Aurelio Matamoros, Kanwal Pratap Singh Raghav, Jeannelyn S. Estrella, Lianchun Xiao, Gauri R. Varadhachary, Shalini Makawita
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-10 (2019)
BMC Cancer
BMC Cancer
Background Sarcomatoid carcinoma of unknown primary (SCUP) is a rare entity of either poorly differentiated carcinoma with sarcoma-like differentiation or a true mixed lineage neoplasm. Limited data regarding clinicopathological profile and managemen
Autor:
Naveen Ramesh, Jennifer Wang, Xuemei Wang, Paul G. Corn, Emi Sei, Shi Ming Tu, Sumit K. Subudhi, Eleni Efstathiou, Ana Aparicio, Christopher J. Logothetis, Timothy C. Thompson, Amado J. Zurita, Patricia Troncoso, Elsa M. Li-Ning-Tapia, Lianchun Xiao, Nicholas Navin, Elisabeth I. Heath
Publikováno v:
Lancet Oncol
Summary Background Taxane–platinum combinations have shown promising activity in metastatic castration-resistant prostate cancers in single-group clinical studies but not in randomised trials. Distinct biological subsets of the disease might derive
Autor:
Lianchun Xiao, George Wilding, Amado J. Zurita, Hirak Basu, James M. Reuben, Mark Titus, Samantha Robertson, Sumankalai Ramachandran, Evan N. Cohen, Nathaniel Wilganowski
Publikováno v:
The ProstateREFERENCES. 81(12)
BACKGROUND Most cancer cells are more glycolytic even under aerobic conditions compared with their normal counterparts. Recent evidence of tumor cell metabolism, however, shows that some tumors also increase mitochondrial oxidative phosphorylation (o